Lataa...
Physiologically‐based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors
Lemborexant, a recently approved dual orexin receptor antagonist for treatment of adults with insomnia, is eliminated primarily by cytochrome P450 (CYP)3A metabolism. The recommended dose of lemborexant is 5 mg once per night, with a maximum recommended dose of 10 mg once daily. A physiologically‐ba...
Tallennettuna:
| Julkaisussa: | CPT Pharmacometrics Syst Pharmacol |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8129715/ https://ncbi.nlm.nih.gov/pubmed/33704920 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12606 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|